NEW YORK & HERZLIYA, Israel – November 3, 2025 – InterCure Ltd., a prominent global cannabis company operating under the Canndoc brand, announced today a significant strategic investment and collaboration with Cannasoul R&D Ltd., a leading pioneer in cannabis research and analytics. The agreements, comprising a Share Purchase Agreement and a Collaboration Agreement, are poised to advance the science and pharmaceutical development of cannabis-based therapeutics.
Deepening Investment in Cannabis Science
The newly formed partnership grants InterCure an initial 28% ownership stake in Cannasoul on a fully diluted basis. Crucially, the agreement includes an exclusive option for InterCure to increase its holding to 51% within the next two years, signaling a strong commitment to integrating Cannasoul’s cutting-edge research capabilities. The Collaboration Agreement formally establishes a framework for joint research, development, and commercialization efforts focused on evidence-based cannabis therapeutics.
Cannasoul’s Analytical Expertise Powers Pharmaceutical Innovation
Cannasoul R&D is globally recognized for its advanced analytical and biological-validation platforms, capable of mapping over 100 cannabinoids and 100 terpenes and flavonoids per cannabis strain. The company’s research, conducted in collaboration with Prof. Dedi Meiri’s laboratory at the Technion – Israel Institute of Technology, spans preclinical and clinical studies across critical areas such as oncology, neurology, and women’s health. This deep scientific foundation and proprietary profiling methodology enable the development of effective, safe, and reliable cannabis-based products and pharmaceuticals.
InterCure’s Vision for Pharmaceutical-Grade Cannabis
InterCure, operating as Canndoc in Israel, is the country’s largest licensed cannabis producer and a leader in offering Good Manufacturing Practices (GMP) certified, pharmaceutical-grade medical cannabis products outside of North America. The company leverages a high-margin, vertically integrated “seed-to-sale” model and a strong distribution network to drive growth in the global cannabis market. This strategic alliance with Cannasoul aligns with InterCure’s ambition to enhance its scientific leadership and accelerate the development of next-generation cannabis therapeutics. InterCure has also focused on expanding its brand offerings, including its partnership with the global cannabis brand Cookies™, with plans for new cannabis products and launches in international markets.
Accelerating Discovery and Global Reach
Under the terms of the agreements, Professor Dedi Meiri, founder of Cannasoul, is expected to chair InterCure’s Scientific Advisory Board. This appointment is intended to facilitate the seamless integration of Cannasoul’s advanced analytics and research into InterCure’s pharmaceutical platform, thereby accelerating translational research and scientific oversight.
“By combining Cannasoul’s established research capabilities with InterCure’s pharmaceutical-grade platform and under the scientific advisory of Prof. Meiri, we plan to accelerate the development of next-generation cannabis therapeutics, expand our international footprint, and drive long-term value for patients and shareholders alike,” stated Alex Rabinovitch, Chief Executive Officer of InterCure.
This partnership emerges at a pivotal moment, as reports indicate the U.S. administration is exploring the rescheduling of cannabis from Schedule I to Schedule III. This potential regulatory shift could unlock unprecedented opportunities for international cannabis companies in the U.S. market, making this alliance strategically timed for future expansion and innovation in new cannabis products.
About InterCure Ltd. (dba Canndoc)
InterCure Ltd. (NASDAQ: INCR / TASE: INCR) is a leading, profitable, and fast-growing cannabis company operating outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market-leading distribution network, best-in-class international partnerships, and a high-margin vertically integrated “seed-to-sale” model to lead the fastest-growing cannabis global market outside of North America.
About Cannasoul R&D Ltd.
Cannasoul R&D is a globally recognized pioneer in cannabis research and analytics, dedicated to developing scientific intellectual property, medical products, and technologies. Founded by Prof. Dedi Meiri, the company utilizes proprietary analytical expertise and advanced platforms to map cannabis compounds and mechanisms of action, supporting R&D activities, pre-clinical and clinical trials. Its research spans oncology, neurology, and women’s health, providing scientific data that meets global standards for developing effective, safe, and reliable cannabis-based products, treatments, and pharmaceuticals.
